“Scientists at the University of New Mexico developed a vaccine targeting the tau protein for Alzheimer's disease, which reduced tau plaques in animal trials (mice and rhesus macaques) and is now being prepared for human clinical trials." Accompanying on-image text: "ALZHEIMER'S VACCINE injection only" / "The world's first Alzheimer's…”
Plain restatementUniversity of New Mexico researchers published a study of an experimental virus-like-particle vaccine targeting phosphorylated tau (pT181). The study reported immune responses in mice and rhesus macaques and reduced tau pathology in mouse models. A Phase 1 human trial is planned.
The study behind this post is real. University of New Mexico researchers published a paper in Alzheimer's & Dementia in March 2025 describing an experimental vaccine that trains the immune system to attack an abnormal form of the tau protein. In genetically modified mice it reduced tau pathology, prevented brain shrinkage, and improved memory. In monkeys it produced a strong antibody response and proved safe, but only three monkeys received the vaccine and it was not shown to clear tau damage in them. A Phase 1 human safety trial has been funded and was planned to begin enrolling in early 2026, so no human has yet been shown to benefit. The post's claim that this is "the world's first Alzheimer's vaccine" is wrong, because tau vaccines have been tested in humans since 2013 and other Alzheimer's vaccines go back further. Also note that tau forms tangles, not plaques, and that the caption uses this legitimate research as a lead-in to sell supplements that have nothing to do with the study.
[drifted from the evidence:] Scientists at the University of New Mexico [drifted from the evidence:] developed a vaccine targeting [drifted from the evidence:] the tau protein for Alzheimer's disease, which reduced tau [drifted from the evidence:] plaques in [drifted from the evidence:] animal trials (mice and rhesus macaques) and [drifted from the evidence:] is now being prepared for human [drifted from the evidence:] clinical trials." Accompanying on-image text: "ALZHEIMER'S VACCINE injection only" / "The world's first Alzheimer's vaccine has been developed.
University of New Mexico [added by the neutral restatement:] researchers published a [added by the neutral restatement:] study of an experimental virus-like-particle vaccine targeting [added by the neutral restatement:] phosphorylated tau [added by the neutral restatement:] (pT181). The study reported immune responses in mice and rhesus macaques and [added by the neutral restatement:] reduced tau pathology in mouse models. A Phase 1 human [added by the neutral restatement:] trial is planned.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The study exists, is real, and is essentially correctly cited by the post, including journal, publication date, senior author Kiran Bhaskar, and institution. A few author surnames in the caption are misspelled (Hulse rendered as Huls, Whelpley as Webley), which is a transcription error, not fabrication.
- UNM scientists did develop a Qβ virus-like-particle vaccine displaying phosphorylated tau at threonine 181.
- The vaccine did produce robust antibody responses in both mice and rhesus macaques.
- Tau pathology was reduced, brain atrophy prevented, and memory and motor function improved in the mouse models.
- Antibodies from immunized animals did bind pathological tau in human Alzheimer's brain tissue.
- Human clinical trials are genuinely in preparation. Funding has been secured, a commercial partner is manufacturing under GMP, and a Phase 1a/1b trial is planned at UNM.
- **Fabricated superlative (on-image text):** "The world's first Alzheimer's vaccine has been developed" is false. Tau vaccines have been in human trials since 2013 with AADvac1, and ACI-35 and its successors have completed Phase 1 and 1b/2a studies. Amyloid-targeting active immunization was tested in humans two decades ago. This vaccine is not the first, and it has not yet been given to a human.
- **Species and efficacy conflation:** the claim states tau was reduced "in animal trials (mice and rhesus macaques)." Pathology reduction was demonstrated in mice. The macaque arm, with only three vaccinated animals, established immune response, safety, and antibody target engagement, not clearance of established tau pathology.
- **Terminology error:** "tau plaques" does not exist as a pathology. Tau forms tangles. This conflates the tau and amyloid hypotheses and may lead readers to think this vaccine addresses the lesions targeted by approved amyloid drugs.
- **Exaggeration:** "performed beyond expectations" and "dramatic reduction" are the poster's language, not the paper's. The paper reports quantified partial reductions such as roughly 40% fewer Gallyas-positive lesions.
- **Temporal overreach:** the post frames a preclinical result plus a not-yet-started Phase 1 safety trial as being at the threshold of one of the biggest medical breakthroughs in decades. A Phase 1a/1b trial measures safety and antibody production, not whether Alzheimer's is prevented or halted. Bhaskar himself said the bottom line is that there is some immunological data and it seems to do well, but that they have to move with caution.
- **Commercial framing:** the caption inserts a supplement promotion linked in the account bio. Nothing in the cited study concerns supplements. This attaches a monetized product pitch to unrelated academic research.
- Whether the Phase 1a/1b trial actually opened enrollment as projected in early 2026. Reporting through mid-2025 describes it as expected, not confirmed started. I did not locate a public trial registry record confirming active recruitment status.
- The exact final trial size, dosing schedule, and participant eligibility criteria were not available in retrieved sources.
- Whether the macaque safety cohort has been extended beyond n=3 per group for regulatory purposes.
The cited study is real, correctly attributed, and correctly dated. Two vaccine doses of pT181-Qß, without any adjuvants, elicited robust antibody responses in two different mouse models of tauopathy (PS19 and hTau) and rhesus macaques. In mouse models, vaccination reduced AT180+ hyperphosphorylated, Sarkosyl insoluble, Gallyas silver positive tau, inflammasomes/neuroinflammation, and improved recognition memory and motor function without inducing adverse T-cell activation. Anti-pT181 antibodies are reactive to pTau in human AD brains, engage pT181+ tau in human brain lysates, and are central nervous system bioavailable. The authors' own interpretation is more measured than the post: the vaccine induced a robust immune response, reduced tau pathology, prevented brain atrophy, and improved memory, and the immunoglobulins from immunized sera engaged the target in vaccinated non-human primates and human AD brains. Future directions state that targeting pT181-positive tau may, in Phase 0/1 clinical trials, validate the safety, immunogenicity, and therapeutic efficacy in patients with AD and related tauopathies. On the clinical trial status, the post is actually behind the news. UNM received early-phase funding to launch a clinical trial for the vaccine, which is exclusively licensed to TheraVac Biologics, Inc. The Phase 1a/1b trial, supported in part by a $1 million grant from the Alzheimer's Association's Part the Cloud initiative, will assess safety, tolerability, and immunogenicity. The trial was expected to begin enrolling participants early in 2026 and to last about 12 months, with half of subjects receiving the active vaccine and half a placebo. ## METHODOLOGY AND CONTEXT - **Design:** Preclinical, multi-species. Two transgenic mouse tauopathy models (PS19 and hTau) plus a small non-human primate immunogenicity and safety cohort. - **Macaque sample size:** very small. Rhesus macaques were immunized with either Qβ (n = 3) or pT181-Qβ (n = 3) at time 0 with two booster immunizations at 4 weeks and 20 weeks, each dose 50 µg administered intramuscularly. - **What the macaques showed:** antibody generation, safety, and target engagement. The macaques were healthy animals. They do not spontaneously develop Alzheimer's-type tau pathology, and the paper does not report clearance of tau pathology in macaque brains. Reduction of tau pathology, brain atrophy prevention, and cognitive and motor improvement were reported in mice. - **Effect size example:** In PS19 mice vaccinated with pT181-Qß, there was a 40% reduction in the number of Gallyas silver positive lesions. That is a meaningful but specific and quantified effect, not an unqualified clearance. - **Terminology:** tau forms neurofibrillary tangles. Plaques are the amyloid-beta lesion. Tau is a naturally occurring protein that helps stabilize neurons, but when phosphorylated it deforms and is ejected from neurons into the extracellular space, creating the tangles characteristic of Alzheimer's and other neurodegenerative diseases. - **Prior art relevant to the "world's first" overlay:** AADvac1 was the first tau immunotherapy to enter clinical trials, containing a tau peptide linked to keyhole limpet haemocyanin, and four Phase I to II trials of it have been completed. ACI-35 was investigated in a Phase 1 clinical trial where it was found to be safe and well tolerated, and second-generation formulations ACI-35.030 and JACI-35.054 were subsequently designed. Since the start of the Phase 1 trial of AADvac1 in 2013, several other clinical tau immunotherapy programmes have been initiated.
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/82d96de21d1e/VoRCNPLL2r8-tbRZh3fGaqh
Ask this case
Answers come only from the case file above; nothing is added.
Is the University of New Mexico tau vaccine study real?
Yes. Researchers at the University of New Mexico published this study in Alzheimer's & Dementia in March 2025, and the study, journal, date, and senior author are correctly cited by the post.
Is this really the world's first Alzheimer's vaccine?
No. Tau-targeting vaccines have been tested in humans since 2013, starting with AADvac1, and another tau vaccine called ACI-35 has also completed Phase 1 trials, so this is not the first.
Did the vaccine actually reduce tau damage in the monkeys?
Not according to the study. The three vaccinated rhesus macaques showed a strong antibody response and no safety problems, but the paper does not report that tau pathology was cleared or reduced in their brains. Reduced tau pathology, prevented brain shrinkage, and improved memory were shown in mice, not monkeys.
Does the vaccine target plaques, as the post claims?
No. Tau forms tangles, not plaques. Plaques are made of a different protein, amyloid-beta, so the post's wording mixes up two separate features of Alzheimer's disease.
Has this vaccine been tested in humans yet?
No. A Phase 1a/1b human safety trial has been funded and was planned to begin enrolling participants in early 2026, but as of the case file no human has received the vaccine or been shown to benefit from it.